Key Takeaways, Study Limitations, and the Broader Implications of CROWN for Patients, Providers, and Payers

In this closing segment, Drs. Lovly and Shaw synthesize the most important lessons from the 7-year CROWN update, address the study's remaining limitations and unanswered questions, and reflect on what this data means for the broader landscape of ALK-positive NSCLC care — from treatment guidelines to payer decision-making to patient survivorship.

Dr. Shaw distills her top three takeaways from the CROWN results. First and foremost is the unprecedented progression-free survival benefit with lorlatinib — the longest reported for any therapy in lung cancer, and arguably in any solid tumor. Second is lorlatinib's remarkable CNS activity, highlighted by the striking finding that 92% of patients remained free of intracranial progression after a median follow-up of 7 years. This speaks not only to lorlatinib's ability to treat existing brain metastases, but to its capacity to prevent their development altogether — a clinically transformative outcome given how frequently ALK-positive patients present with or develop CNS disease. Third is the importance of proactive, ongoing safety management, underscoring that the side effect profile, while manageable, requires sustained attention across the full duration of therapy.

On the question of study limitations, Dr. Shaw acknowledges that biomarker analyses identifying predictors of early progression versus durable response remain preliminary, and that the overall survival data, though highly anticipated, are not yet mature enough to report. She expresses strong confidence, however, that survival outcomes will ultimately prove equally impressive. When asked whether the 7-year update changes the treatment landscape or simply reinforces existing practice, Dr. Shaw is clear: while current NCCN guidelines list second- and third-generation ALK inhibitors as co-equal preferred options, the magnitude of the CROWN data compels her to elevate lorlatinib above the others. The segment closes with two resonant calls to action from Dr. Lovly — a reminder that biomarker testing remains the essential gateway to delivering these life-changing therapies, and an introduction to the ALK Positive patient advocacy community as a vital resource for patients and families navigating this diagnosis.